Hyperamylasemia in Inflammatory Bowel Disease: Report of a case with literature review

K.H. Katsanos\textsuperscript{1}, G. Kolios\textsuperscript{2}, G.V. Tsianos\textsuperscript{3}, E.V. Tsianos\textsuperscript{1}

\textbf{SUMMARY}
It has been suggested that in patients with inflammatory bowel disease (IBD) there is subclinical pancreatic involvement. A 22-year-old male with Crohn’s disease of the terminal ileum, diagnosed four years earlier was admitted in our hospital because of persistent asymptomatic mild hyperamylasemia (serum amylase 135 UI/ml) during azathioprine treatment. Patient personal history was unremarkable and there was no evidence of any other extraintestinal manifestations. Physical examination was within normal limits and upper gastrointestinal tract endoscopy with abdominal MRI and MRCP were normal. During admission it was decided to switch from azathioprine to methotrexate in order to exclude the possibility of azathioprine-related idiopathic pancreatitis. However, serum amylase values did not subsided. An additional MRCP performed at that time was normal. Subsequent serum isoamylase determination showed pancreatic iso-enzyme predominance (P-isoenzyme). As patient transaminases were markedly increased during methotrexate therapy, it was decided to finally switch the patient again to azathioprine as the diagnosis of chronic idiopathic pancreatitis secondary to Crohn’s disease seemed more probable. On the two-year laboratory follow up the patient still had mild asymptomatic hyperamylasemia. Differential diagnosis of hyperamylasemia in IBD includes overview of general and disease specific causes of hyperamylasemia, as well as laboratory investigative methods on amylase typing and subtyping. In the absence of specific indications this hyperamylasemia requires no further investigation.

\textbf{Key words:} hyperamylasemia, Crohn’s disease, ulcerative colitis, isoamylases.

\textbf{INTRODUCTION}
The first suggestion of a significant association between pancreatic lesions and inflammatory bowel disease (IBD) was reported in 1950 by Ball et al.\textsuperscript{1} who found 14\% and 53\% of macroscopic and histologic lesions, respectively, in a postmortem study of patients with ulcerative colitis (UC). The same team found mild to moderate pancreatic fibrosis at necropsy in 15 out of 39 patients with Crohn’s disease (CD).

The first report on hyperamylasemia in inflammatory bowel disease (IBD) was from Legge D et al. in 1971\textsuperscript{2}. This was the first report of pancreatitis as a complication of regional enteritis of the duodenum. The authors report 3 out of 10 patients with “regional enteritis” involving the duodenum who were diagnosed with pancreatitis, as judged by elevated values for serum amylase and, in 2 of the 3 patients by the gross appearance of the pancreas at operation.

Whether the pancreas can be involved in the granulomatous inflammation of Crohn’s disease (CD) is not known. Granulomas isolated to the pancreas in patients with sarcoidosis or tuberculosis has been suggested as a cause of acute or chronic pancreatitis in such cases. They have, however not been demonstrated in postmortem studies or pancreatic biopsies among patients with CD and pancreatitis\textsuperscript{3}. Pancreatitis in inflammatory bowel disease (IBD) is an uncommon complication and is difficult to diagnose in patients with IBD. IBD is a chronic inflammatory disease of the gastrointestinal tract, including the ileum, colon, and small intestine. It includes two major subtypes: ulcerative colitis (UC) and Crohn’s disease (CD). The diagnosis of IBD is usually based on the clinical presentation, endoscopic findings, and histological examination of the affected tissues. The presence of hyperamylasemia, which is defined as an increase in serum amylase activity above the upper limit of normal, can be a useful indicator of pancreatic involvement in patients with IBD. Hyperamylasemia can be caused by both general and disease-specific factors, and its presence can help in the differential diagnosis of IBD. In this case report, we present the clinical findings of a 22-year-old male with Crohn’s disease of the terminal ileum who was admitted to our hospital because of persistent asymptomatic mild hyperamylasemia during azathioprine treatment. The patient had no extraintestinal manifestations, and physical examination was within normal limits. Upper gastrointestinal tract endoscopy with abdominal MRI and MRCP were normal. During admission, it was decided to switch from azathioprine to methotrexate in an attempt to exclude azathioprine-related idiopathic pancreatitis. However, serum amylase values did not subside after the MRCP, which was normal. Subsequent serum isoamylase determination showed pancreatic iso-enzyme predominance (P-isoenzyme). As patient transaminases were markedly increased during methotrexate therapy, it was decided to finally switch the patient again to azathioprine as the diagnosis of chronic idiopathic pancreatitis secondary to Crohn’s disease seemed more probable. On the two-year laboratory follow up, the patient still had mild asymptomatic hyperamylasemia. Differential diagnosis of hyperamylasemia in IBD includes an overview of general and disease-specific causes of hyperamylasemia, as well as laboratory investigative methods on amylase typing and subtyping. In the absence of specific indications, this hyperamylasemia requires no further investigation.

\textbf{Key words:} hyperamylasemia, Crohn’s disease, ulcerative colitis, isoamylases.
disease in children is generally anecdotal. According to another study, in ulcerative colitis (UC) a patient’s pancreatitis was a prior manifestation in 58% of cases, while in patients with CD, pancreatitis appeared after disease onset in 58% of cases. In a study of exocrine pancreatic function in 143 CD patients, using Lundh meal test and duodenal aspirates analysis, exocrine pancreatic function was to be shown decreased in this group of patients. The reason for this decreased pancreatic function in patients with CD is unclear. According to authors at least two factors seem to be responsible for impaired pancreatic function in Crohn’s disease: firstly disease activity and secondly localization or extent of disease.

Two different isoenzyme types constitute total serum a-amylase: The S-isoenzyme (salivary type, predominates in serum) and the P-isoenzyme (predominates in urine). It has been suggested that in patients with inflammatory bowel disease there is a subclinical pancreatic involvement. In fact, it has been shown that in ulcerative colitis patients, the ratio between pancreatic and salivary isoamylase subtypes is reversed in favour of pancreatic isoenzyme, compared to healthy controls. In another study for oral findings in patients with active or inactive Crohn’s disease, it has been shown that levels of salivary amylase did not differ with respect to the activity of Crohn’s disease.

Herein we present a case of a young Crohn’s disease patient with persistent hyperamylasemia of unknown origin, in whom serum isoamylase determination showed pancreatic isoenzyme predominance.

**CASE REPORT**

A 22-year-old male with Crohn’s disease of the terminal ileum, diagnosed four years earlier was admitted to our hospital because of persistent asymptomatic mild hyperamylasemia. The patient was on azathioprine maintenance dose treatment (150mg/day).

At the time of admission, Crohn’s disease activity index (CDAI) was 138, while peripheral blood count showed nothing remarkable. Routine biochemical analysis showed serum amylase 135 UI/ml (normal up to 90 UI/ml), while all other biochemical tests showed nothing remarkable. Patient body mass index (BMI) was in the upper normal limit, while fasting cholesterol and triglycerides values did not exceed the upper normal limit.

The patient is personal history was unremarkable and there was no evidence of any other extraintestinal manifestation related to Crohn’s disease. Family history was unremarkable and the patient had one brother with no history of any kind of chronic disease. The patient was not a smoker and denied any alcohol intake.

Physical examination showed nothing remarkable and upper gastrointestinal tract endoscopy was within normal limits. Unselected random gastric and duodenal biopsies did not show any evidence of upper gastrointestinal tract Crohn’s disease involvement. Additionally, routine radiological examinations, including abdominal ultrasonography, were within normal limits.

By careful review of the patient’s records it became evident that since initial diagnosis of Crohn’s disease and before azathioprine introduction, serum amylase was persistently mildly increased ranging from 107 to 125 UI/ml (normal range up to 90 UI/ml), while patient was continuously asymptomatic.

At the time of diagnosis, four years ago, the patient was initially started on therapy with corticosteroids with subsequent tapering (15 mg of orally administered prednizolone), and azathioprine at a dose of 2mg/kg of body weight (150mg/day). The patient was discharged a few days later but in the three-month regular follow up amylase was still elevated, although patient still remained asymptomatic. Abdominal magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) were performed then and did not show anything remarkable. Peripheral blood test and routine biochemistry remained within normal limits except for amylase. Immunology showed antinuclear autoantibodies titer of 1/320, that had subsided to normal titers by the next three-month follow-up.

During this last admission it was decided to switch azathioprine to oral methotrexate (dose of 15mg/week) in order to exclude the possibility of azathioprine-related idiopathic pancreatitis. However, in the six-month follow-up, serum amylase values had not subsided to normal values despite methotrexate introduction. A second MRCP, which was performed at that time, was normal. Subsequent serum isoamylase determination showed pancreatic isoenzyme (P-isoenzyme) predominance (Figure).

As patient transaminases were markedly increased (5-fold) during methotrexate therapy, it was finally decided to switch the patient back to azathioprine, as exclusion diagnosis of chronic idiopathic pancreatitis secondary to Crohn’s disease seemed more logical, compared to that of possible azathioprine-related toxicity.
levels of serum amylase were associated with extensive colonic disease and high histological activity. In addition, amylase was significantly elevated in patients with primary sclerosing cholangitis and smokers showed higher urinary amylase levels than non- and ex-smokers. In fact this patient was neither a smoker nor an ex-smoker, while MRCP failed to show any biliary tract involvement. However it seems that factors related to hyperamylasemia in IBD have not yet been well recognized as controversial results exist in the literature (Table 1).

A total of 211 medical files from our IBD outpatient clinic were retrospectively reviewed for evidence of hyperamylasemia (serum amylase levels over 90 UI/ml at least once). Hyperamylasemia (range 92-1648 UI/ml) was recorded, at least once, in 21 out of 188 patients (11.2%) (Table 2). Only one patient (0.5%) with CD and hyperamylasemia was symptomatic and developed pancreatitis twice after short-term azathioprine administration (highest amylase value 1648 UI/ml). No correlation of hyperamylasemia with disease extension (UC or CD) was documented.

Differential diagnosis of hyperamylasemia in IBD includes overview of general and disease specific causes of hyperamylasemia, as well as laboratory investigation on amylase typing and subtyping. Abdominal imaging, as well as specific pancreatic function tests, may also be of help when available. Causes of hyperamyla-semia with or without evidence of pancreatitis in IBD may be general or disease specific, while probable exceptional cases with co-existence of general and disease-specific causes may also occur in clinical practice.

The general causes of hyperamylasemia include: 1) Pancreatic diseases (acute pancreatitis, chronic pancreatitis, pancreatic cancer), 2) Hepato-biliary diseases (gallstones, choledochal stones, biliary tract cancer), 3) Acute abdo-

**DISCUSSION**

Pancreatitis is a rare, extraintestinal manifestation of inflammatory bowel disease, while asymptomatic hyperamylasemia is a frequent laboratory finding that usually requires no further investigation.

The highest prevalence of hyperamylasemia ever reported was 44% and 64% of UC and CD patients respectively. However these numbers seem to be extremely high for any case series. A study with 136 IBD patients showed that asymptomatic elevation of serum amylase without symptoms of pancreatitis could occur in up to 14% of patients. In a study with 237 patients diagnosed with IBD, hyperamylasemia was found in 11% of the group. The corresponding prevalence in CD and in ulcerative colitis were 17% and 9% respectively. High

levels of serum amylase were associated with extensive colonic disease and high histological activity. In addition, amylase was significantly elevated in patients with primary sclerosing cholangitis and smokers showed higher urinary amylase levels than non- and ex-smokers. In fact this patient was neither a smoker nor an ex-smoker, while MRCP failed to show any biliary tract involvement. However it seems that factors related to hyperamylasemia in IBD have not yet been well recognized as controversial results exist in the literature (Table 1).

A total of 211 medical files from our IBD outpatient clinic were retrospectively reviewed for evidence of hyperamylasemia (serum amylase levels over 90 UI/ml at least once). Hyperamylasemia (range 92-1648 UI/ml) was recorded, at least once, in 21 out of 188 patients (11.2%) (Table 2). Only one patient (0.5%) with CD and hyperamylasemia was symptomatic and developed pancreatitis twice after short-term azathioprine administration (highest amylase value 1648 UI/ml). No correlation of hyperamylasemia with disease extension (UC or CD) was documented.

Differential diagnosis of hyperamylasemia in IBD includes overview of general and disease specific causes of hyperamylasemia, as well as laboratory investigation on amylase typing and subtyping. Abdominal imaging, as well as specific pancreatic function tests, may also be of help when available. Causes of hyperamyla-semia with or without evidence of pancreatitis in IBD may be general or disease specific, while probable exceptional cases with co-existence of general and disease-specific causes may also occur in clinical practice.

The general causes of hyperamylasemia include: 1) Pancreatic diseases (acute pancreatitis, chronic pancreatitis, pancreatic cancer), 2) Hepato-biliary diseases (gallstones, choledochal stones, biliary tract cancer), 3) Acute abdo-

---

**Table 1.** Prevalence of asymptomatic hyperamylasemia in IBD and its correlation with several clinical parameters.

| Author            | Hyperamylasemia % | Disease Activity | Disease Extension | Duodenal Disease Location | Disease Treatment | Disease Duration | PSC* | Smoking | Weight | Sex | Sex
|-------------------|--------------------|------------------|-------------------|--------------------------|------------------|------------------|------|---------|-------|-----|------
| Tromm A, et al.   | 15.3               | _                | _                 | _                        | _                | _                | _    | _       | _     | _   | _    |
| Heikiaus B, et al.| 17                 | +                | +                 | _                        | _                | _                | +    | +       | _     | _   | _    |
| Katz S, et al.    | 8                  | _                | _                 | _                        | _                | _                | _    | _       | _     | _   | _    |
| Le large-Guitiered| 14.5               | +                | +                 | +                        | _                | _                | +    | _       | _     | _   | _    |
| Bohemeyer B.      | 14                 | _                | +                 | _                        | _                | _                | _    | _       | _     | _   | _    |
| Barthe M, et al.  | 64                 | _                | _                 | _                        | _                | _                | _    | _       | _     | _   | _    |

*PSC= Primary Sclerosing Cholangitis, **F= females, M= males, + = positive correlation, – = Negative correlation
Table 2. Disease characteristics of hyperamylasemic IBD patients from Northwest Greece with (AMS normal range 0-90 UI/ml).

<table>
<thead>
<tr>
<th>Age/Sex</th>
<th>IBD type</th>
<th>Therapy</th>
<th>Extension</th>
<th>Disease duration (ys)</th>
<th>PSC highest</th>
<th>Smoking</th>
<th>Alcohol</th>
<th>AMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>57, M</td>
<td>UC</td>
<td>S</td>
<td>LUC</td>
<td>15</td>
<td>-</td>
<td>Yes</td>
<td>Yes</td>
<td>182</td>
</tr>
<tr>
<td>39, M</td>
<td>CD</td>
<td>S, Aza, Remicade</td>
<td>Ileocolitis</td>
<td>18</td>
<td>-</td>
<td>Yes</td>
<td>No</td>
<td>350</td>
</tr>
<tr>
<td>30, F</td>
<td>UC</td>
<td>S</td>
<td>TUC</td>
<td>15</td>
<td>-</td>
<td>No</td>
<td>No</td>
<td>210</td>
</tr>
<tr>
<td>72, M</td>
<td>UC</td>
<td>S</td>
<td>TUC</td>
<td>17</td>
<td>-</td>
<td>Yes</td>
<td>Yes</td>
<td>189</td>
</tr>
<tr>
<td>39, F</td>
<td>UC</td>
<td>S</td>
<td>TUC</td>
<td>16</td>
<td>-</td>
<td>No</td>
<td>No</td>
<td>115</td>
</tr>
<tr>
<td>38, M</td>
<td>UC</td>
<td>S, M</td>
<td>LUC</td>
<td>17</td>
<td>-</td>
<td>No</td>
<td>No</td>
<td>98</td>
</tr>
<tr>
<td>63, M</td>
<td>CD</td>
<td>S, M, Remicade</td>
<td>ileitis</td>
<td>5</td>
<td>-</td>
<td>Yes</td>
<td>Yes*</td>
<td>92</td>
</tr>
<tr>
<td>50, M</td>
<td>CD</td>
<td>S, M, MTX</td>
<td>ileitis</td>
<td>11</td>
<td>-</td>
<td>Yes</td>
<td>Yes</td>
<td>1648</td>
</tr>
<tr>
<td>62, F</td>
<td>UC</td>
<td>S, M</td>
<td>TUC</td>
<td>19</td>
<td>-</td>
<td>No</td>
<td>No</td>
<td>220</td>
</tr>
<tr>
<td>73, F</td>
<td>UC</td>
<td>S</td>
<td>LUC</td>
<td>15</td>
<td>-</td>
<td>No</td>
<td>No</td>
<td>95</td>
</tr>
<tr>
<td>48, M</td>
<td>UC</td>
<td>S</td>
<td>LUC</td>
<td>14</td>
<td>-</td>
<td>Yes</td>
<td>No</td>
<td>363</td>
</tr>
<tr>
<td>72, M</td>
<td>UC</td>
<td>S</td>
<td>LUC</td>
<td>10</td>
<td>-</td>
<td>Yes</td>
<td>No</td>
<td>113</td>
</tr>
<tr>
<td>87, M</td>
<td>UC</td>
<td>S</td>
<td>LUC</td>
<td>15</td>
<td>-</td>
<td>Yes</td>
<td>No</td>
<td>153</td>
</tr>
<tr>
<td>53, M</td>
<td>CD</td>
<td>S, Aza</td>
<td>ileitis</td>
<td>3</td>
<td>-</td>
<td>Yes</td>
<td>Yes</td>
<td>112</td>
</tr>
<tr>
<td>34, M</td>
<td>CD</td>
<td>S, M, Aza</td>
<td>ileitis</td>
<td>5</td>
<td>-</td>
<td>Yes</td>
<td>No</td>
<td>138</td>
</tr>
<tr>
<td>35, F</td>
<td>UC</td>
<td>S, M</td>
<td>TUC</td>
<td>2</td>
<td>-</td>
<td>No</td>
<td>Yes</td>
<td>120</td>
</tr>
<tr>
<td>80, M</td>
<td>UC</td>
<td>M, Aza</td>
<td>LUC</td>
<td>15</td>
<td>-</td>
<td>No</td>
<td>No</td>
<td>255</td>
</tr>
<tr>
<td>65, F</td>
<td>UC</td>
<td>S, Aza</td>
<td>LUC</td>
<td>15</td>
<td>-</td>
<td>No</td>
<td>No</td>
<td>200</td>
</tr>
<tr>
<td>67, F</td>
<td>UC</td>
<td>S</td>
<td>LUC</td>
<td>12</td>
<td>-</td>
<td>No</td>
<td>Yes</td>
<td>188</td>
</tr>
<tr>
<td>52, F</td>
<td>CD</td>
<td>S, M, Aza</td>
<td>ileocolitis</td>
<td>16</td>
<td>-</td>
<td>No</td>
<td>No</td>
<td>102</td>
</tr>
<tr>
<td>44, M</td>
<td>UC</td>
<td>S</td>
<td>TUC</td>
<td>6</td>
<td>-</td>
<td>No</td>
<td>No</td>
<td>1175</td>
</tr>
</tbody>
</table>

Abbreviations used in the table: M= male, F= female, CD= Crohn’s disease, UC= ulcerative colitis, T= Total, L= Left, S= mesalazine, M= methylprednisolone, Aza= Azathioprine, MTX= methotrexate.

* hyperlipidemia also (CHOL=368 mg/dl)

minal pain (peptic ulcer perforation, peritonitis, intestinal obstruction, appendicitis, acute vascular episode, 4) Salivary gland diseases (measles, lithiasis, oral surgery), 5) Other causes such as chronic renal disease, alcohol, macroamylasemia, isoamylase production from malignant tumors, metabolic disorder, head trauma, hereditary pancreatitis, hyperlipidemia, hypercalcemia, parenteral nutrition, gestation, prostate diseases, S-type hyperamylasemia and several drugs including trimethoprim/ sulfamethoxazole, corticosteroids, ACTH, estrogens, azathioprine, tetracycline, rifampicin, thiazidic diuretics, salicylates, anticoagulants, paracetamol and morphine. All the above causes were excluded by patient medical history and clinical and laboratory follow up.

Disease-specific causes of hyperamylasemia in IBD can be generally categorized as following: 1) Idiopathic hyperamylasemia as extraintestinal manifestation of IBD which seems the most probable cause in this particular patient. According to one study, no alteration of intestinal permeability could be demonstrated in patients with CD or UC. Painless hyperamylasemia or hyperlipasemia were found in 15.8% of CD patients and in 21.3% of UC patients without morphological abnormalities on abdominal ultrasound in the study by Tromm et al.13 2) Pancreatic damage. Probable mechanisms may be the following: pancreatic autoantibodies, pancreatic duct strictures, granulomas and interlobular or perilobular fibrosis. Some investigators have found a high occurrence of autoantibodies against pancreatic tissue in serum from patients with CD, but contradictory reports still exist about their clinical significance. Autoantibodies to pancreas (PAB) are characterized by high disease specificity, although the incidence in Crohn’s disease is low. In addition, it has been shown that families of patients with CD or UC had the same PAB subtypes.14

Although in this patient PAB were not tested, abdominal MRI and MRCP did not show any kind of macroscopic pancreatic involvement. 3) Drug-induced
hyperamylasemia, including azathioprine (or 6 MP), corticosteroids, sulfasalazine (or 5-ASA) in oral and rectal administration, metronidazole and Infliximab use. In their review of 676 cases of regional enteritis up to the early 50s’ Crohn and Yarnis do not mention acute pancreatitis. First reports on acute pancreatitis were in transplant recipients receiving azathioprine, which were followed later on by reports on acute pancreatitis as a complication of azathioprine therapy in regional enteritis\textsuperscript{15}. In an experimental study with isolated ex vivo perfused canine pancreas it was shown that azathioprine administration resulted in a significant increase in secretory volume and bicarbonate output and profound depression of trypsin output compared to controls.\textsuperscript{16} Azathioprine was associated with pancreatitis in at least 4.4\% of patients receiving it in the National Cooperative Crohn’s Disease Study.\textsuperscript{17} In 6 out of 113 patients with CD who developed pancreatitis, all cases occurred with the first 21 days of treatment. 6-MP has an important role in the IBD treatment. Its most frequent short-term complication has proved to be pancreatitis, which has an obscure pathophysiology. In a series of 400 IBD patients, 3.25\% of them (13 patients) developed pancreatitis.\textsuperscript{18} In all cases, when 6-MP was discontinued symptoms and signs returned to normal over a period of 1-11 days. Rechallenge with low doses of 6-MP produced again the same symptoms. In the authors opinion this reaction seems to represent a type II (cytotoxic-complement-mediated) or type IV (sensitized T-lymphocyte-mediated) response.\textsuperscript{18}

The pancreatic toxicity of oral 5-ASA derivatives used for the treatment of IBD remains controversial. This patient was never started on any kind of 5-ASA derivative. In a series of patients receiving mesalazine or olsalazine, acute pancreatitis occurred in 71.4\% of cases during the first month of treatment.\textsuperscript{19} An example of acute pancreatitis developing five weeks after initial treatment with 5-ASA for severe Crohn’s disease has been reported in a 37 year-old female patient.\textsuperscript{20} Acute pancreatitis from 5-ASA derivatives reeded within a few hours after the drug had been discontinued and pancreatic enzyme levels returned to normal in the course of the next 2-3 weeks in another case study.\textsuperscript{21} The authors support the scenario of allergic reaction to 5-ASA derivatives in these patients. In another case of acute pancreatitis with elevated serum amylase levels and ultrasonographic criteria of inflamed pancreas, it has been suggested that the sulfonamide component of sulfasalazine was responsible for this adverse effect because of the structural similarity of the sulfonamides to the thiazide diuretics, which are a well recognized cause of drug induced pancreatitis.\textsuperscript{22} Furthermore, oral and rectal mesalazine administration, salicylicazosulfapyridine and disodium azodisalicylate therapy can also induce reversible pancreatitis.\textsuperscript{23-25} Metronidazole use has been also associated with pancreatitis\textsuperscript{26}.

Finally, the role of infliximab (monoclonal chimeric antibody against TNFa) in inducing hyperamylasemia or even pancreatitis remains obscure at the moment, as controversial reports on its use in such cases exist.\textsuperscript{27-28} 4) Macroamylasemia may also rarely occur in IBD\textsuperscript{29,31} and was excluded during amylase electrophoresis in this patient. 5) Duodeno-pancreatic fistula between the duodenum and pancreatic ducts also may be a triggering factor.\textsuperscript{18} 6) Ampullary damage from duodenal Crohn’s disease and reflux of duodenal contents in the pancreatic duct could be another cause.\textsuperscript{3} 7) Direct ampullary involvement in Crohn’s disease causing obstruction of pancreatic flow may also induce pancreatitis.\textsuperscript{5} 8) Intestinal complications such as ischemia, necrosis, perforation, obstruction may also cause hyperamylasemia from bowel and not from pancreatic origin.\textsuperscript{32} However upper gastrointestinal tract endoscopy and subsequent histology were negative. 9) Intravenous fat emulsions may rarely cause pancreatitis and this may be more likely in CD although here it was not the case. It is unclear whether hypertriglyceridemia secondary to intravenous fat emulsions, is a perquisite for this complication to occur.\textsuperscript{33} In addition, hypertriglyceridemia resulting from parenteral nutrition may be caused by glucose intolerance and not intravenous fat emulsion administration.\textsuperscript{34}

Methods of clinical investigation of hyperamylasemia in inflammatory bowel disease may include all methods studying for exocrine pancreatic function. The value of standard endoscopy and of ERCP or MRCP methods is undisputable as, in a series of 237 IBD patients, the prevalence of co-existing cholangiographic and pancreaticographic duct changes was found to be 4.6\%.\textsuperscript{35} In this young patient, MRCP was preferred rather than ERCP as no signs of further clinical or laboratory deterioration were evident on long-term follow up.

Prevention of pancreatitis by weekly amylase assay in the first weeks of treatment in patients with IBD treated with azathioprine may represent a follow up strategy in such cases.\textsuperscript{36-38} This hyperamylasemia, in the absence of appropriate indications, requires no investigation. These indications arise from general and disease specific causes of hyperamylasemia discussed in previous paragraphs. These causes must always be overviewed when initial diagnosis of hyperamylasemia in any IBD patient occurs.
REFERENCES


31. Levitt MD, Ellis C. A rapid and simple assay to determine if macroamylase is the cause of hyperamylasemia. Gastroenterology 1982; 83:378.


